by Elena Iemma | Nov 4, 2021 | News
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...
by Elena Iemma | Apr 27, 2021 | News
PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising...
by Adam | Dec 15, 2020 | News
PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
by Adam | Nov 6, 2019 | News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Adam | Oct 23, 2019 | News
Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....